WO2020156683A1 - Aleglitazar for use in the treatment or prevention of major adverse cardiac events - Google Patents

Aleglitazar for use in the treatment or prevention of major adverse cardiac events Download PDF

Info

Publication number
WO2020156683A1
WO2020156683A1 PCT/EP2019/052539 EP2019052539W WO2020156683A1 WO 2020156683 A1 WO2020156683 A1 WO 2020156683A1 EP 2019052539 W EP2019052539 W EP 2019052539W WO 2020156683 A1 WO2020156683 A1 WO 2020156683A1
Authority
WO
WIPO (PCT)
Prior art keywords
aleglitazar
cardiac events
major adverse
adverse cardiac
treatment
Prior art date
Application number
PCT/EP2019/052539
Other languages
French (fr)
Inventor
Harold V. BARRON
Michele Bortolini
Regina DUTTLINGER
Carl Anders SVENSSON
Jin Tian
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Priority to PCT/EP2019/052539 priority Critical patent/WO2020156683A1/en
Publication of WO2020156683A1 publication Critical patent/WO2020156683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings

Definitions

  • the present invention relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events, in particular in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia.
  • Aleglitazar is (S)-2-methoxy-3- ⁇ 4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]- benzo[b]thiophen-7-yl ⁇ -propionic acid. It belongs to the class of Peroxisome Proliferator Activated Receptors (PPAR) agonists.
  • PPAR Peroxisome Proliferator Activated Receptors
  • Peroxisome Proliferator Activated Receptors are members of the nuclear hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes thereof have been identified and cloned. These include PPAR alpha, PPAR beta (also known as PPAR delta) and PPAR gamma. There exist at least two major iso forms of PPAR gamma. While PPAR gamma 1 is ubiquitously expressed in most tissues, the longer isoform PPAR gamma2 is almost exclusively found in adipocytes. In contrast, PPAR alpha is predominantly expressed in the liver, kidney and heart. PPARs modulate a variety of body responses including glucose and lipid homeostasis, cell differentiation, inflammatory responses and cardiovascular events.
  • Aleglitazar is a potent, balanced dual PPAR alpha/gamma agonist. It combines the PPAR alpha with the PPAR gamma agonist effects.
  • AleCardio was a randomized, double-blind, placebo controlled, multicenter study to evaluate the effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome (ACS) in patients with type 2 diabetes mellitus.
  • the study design has previously been published in Lincoff et a , JAMA 2014; 311(15):1515-1525. and Lincoff et ah, Am Heart J. 2013;166(3):429-434.
  • the study protocol was approved by the institutional review board of each center and all patients gave written informed consent. The study was overseen by steering and safety committees. The steering committee oversaw the study design, the study conduction and the study data analysis.
  • a Data and Safety Monitoring Board consisting of independent physicians and statisticians with access to unblended data, monitored the safety of study. 7,226 patients who were hospitalized for ACS with either established or newly diagnosed type 2 diabetes were recruited between February 2010 and May 2012 from 722 centers in 26 countries. The study was planned to continue until patients were folio wed-up for at least 2.5 years and 950 primary end point events were positively adjudicated. However, the trial was terminated in July 2013 following the DSMB’s recommendation and 704 primary end points events (74% of those projected) had been positively adjudicated by December 17, 2013.
  • DSMB Data and Safety Monitoring Board
  • Acute coronary syndrome included myocardial infarction, with or without ST segment elevation on the electrocardiogram, or biomarker negative unstable angina.
  • Exclusion criteria included symptomatic heart failure, hospitalization with heart failure within the previous 12 months, severe peripheral edema, estimated glomerular filtration rate of ⁇ 45 mE/min/1 .73 m 2 ) or fasting triglyceride level greater than 400 mg/dL.
  • Patients could be randomized at hospital discharge following the qualifying ACS event or after a screening period of no longer than 12 weeks to allow stabilization of their clinical condition, completion of planned revascularization
  • thiazolidinediones or fibrates was not permitted. Patients returned for outpatient visits at 1 , 3, 6, 9, and 12 months following randomization, followed by alternating visits and phone contact every third month thereafter. The study drug was not interrupted until the repeated test of serum creatinine value was superior to 50% increase over the baseline visit.
  • Weight (Kg) mean 82.2 85.3
  • Figure 1 represents the time to first event of MACE endpoint in AleCardio patients with baseline eGFR ⁇ 60mL/min and HDL-C ⁇ 40mg/dL.
  • Figure 2 shows the comparision of MACE endpoint in different subgroups.
  • Major adverse cardiac events MACE: composite of cardiovascular death, non-fatal MI or non- fatal stroke.
  • the invention thus relates to aleglitazar for use in treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia.
  • the invention also relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having a GFR inferior to 60 mL/min and a HDL-C level inferior to 40 mg/dL.
  • the invention further relates to aleglitazar for use as defined above, wherein chronic kidney disease is diabetic kidney disease.
  • the invention further relates to aleglitazar for use as defined above, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non- fatal stroke.
  • the invention also relates to aleglitazar for use as defined above, wherein the patient is of Asian ethnicity.
  • Asian ethnicity refers to a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including, for example,
  • CKD is generally defined as kidney damage for at least 3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR; or GFR ⁇ 60 mL/min/1 73m2 for at least 3 months, with or without kidney damage.
  • DKD is a subset of CKD, wherein the patient has diabetes induced kidney injury and albuminuria.
  • Type 2 Diabetes like CKD and DKD, is a well characterized disease and its diagnosis criteria are established by the World Health Organization.
  • the invention also relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity.
  • the invention relates in particular to aleglitazar for use as defined above wherein aleglitazar is for oral use at a dose of 150 ug once a day.
  • the invention further relates to:
  • aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia;
  • aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient having a GFR inferior to 60 mF/min and a HDF-C level inferior to 40 mg/dF;
  • chronic kidney disease is diabetic kidney disease
  • the invention also relates to the use of aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity.
  • the invention relates in particular to a use as defined above wherein aleglitazar is for oral use at a dose of 150 ug once a day.
  • the invention further relates to:
  • a method for the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia comprising the administration of aleglitazar to a patient in need thereof;
  • a method for the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia comprising the administration of aleglitazar to a patient in need thereof;
  • a method as defined above, wherein chronic kidney disease is diabetic kidney disease;
  • a method as defined above, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non-fatal stroke; and
  • the invention aslo relates to a method for the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity comprising the administration of aleglitazar to a patient in need thereof.
  • the invention relates in particular to method as defined above wherein aleglitazar is orally administered at a dose of 150 ug once a day.
  • the patient can in particular be a patient suffering from acute coronary syndrome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

- 9 - Abstract The invention relates to the use of aleglitazar in the treatment or prevention of major adverse cardiac events as defined in the description and in the claims.

Description

Aleglitazar for use in the treatment or prevention of major adverse cardiac events
The present invention relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events, in particular in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia. Aleglitazar is (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]- benzo[b]thiophen-7-yl} -propionic acid. It belongs to the class of Peroxisome Proliferator Activated Receptors (PPAR) agonists. Aleglitazar is described in WO 02/092084.
Peroxisome Proliferator Activated Receptors (PPAR) are members of the nuclear hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes thereof have been identified and cloned. These include PPAR alpha, PPAR beta (also known as PPAR delta) and PPAR gamma. There exist at least two major iso forms of PPAR gamma. While PPAR gamma 1 is ubiquitously expressed in most tissues, the longer isoform PPAR gamma2 is almost exclusively found in adipocytes. In contrast, PPAR alpha is predominantly expressed in the liver, kidney and heart. PPARs modulate a variety of body responses including glucose and lipid homeostasis, cell differentiation, inflammatory responses and cardiovascular events.
Aleglitazar is a potent, balanced dual PPAR alpha/gamma agonist. It combines the PPAR alpha with the PPAR gamma agonist effects.
In the randomized clinical trial AleCardio (Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus), although aleglitazar reduced hemoglobin AIC and improved serum HDL-C and triglyceride levels, consistently with other previous PPAR studies, it did not significantly decrease the incidence of cardiovascular death, myocardial infarction or stroke in the overall population. Additionally, aleglitazar treatment showed increased risks of heart failure, renal dysfunction, bone fracture, GI bleeding and hypoglycemia.
DP/31.01.19 However, aleglitazar surprisingly demonstrated in this study a positive effect on relative risk reduction of major adverse cardiac events (MACE) in the subgroup of patients who have chronic kidney disease and dyslipidemia. The safety profile was also balanced in this subgroup.
AleCardio was a randomized, double-blind, placebo controlled, multicenter study to evaluate the effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome (ACS) in patients with type 2 diabetes mellitus. The study design has previously been published in Lincoff et a , JAMA 2014; 311(15):1515-1525. and Lincoff et ah, Am Heart J. 2013;166(3):429-434. The study protocol was approved by the institutional review board of each center and all patients gave written informed consent. The study was overseen by steering and safety committees. The steering committee oversaw the study design, the study conduction and the study data analysis. A Data and Safety Monitoring Board (DSMB), consisting of independent physicians and statisticians with access to unblended data, monitored the safety of study. 7,226 patients who were hospitalized for ACS with either established or newly diagnosed type 2 diabetes were recruited between February 2010 and May 2012 from 722 centers in 26 countries. The study was planned to continue until patients were folio wed-up for at least 2.5 years and 950 primary end point events were positively adjudicated. However, the trial was terminated in July 2013 following the DSMB’s recommendation and 704 primary end points events (74% of those projected) had been positively adjudicated by December 17, 2013.
The study enrolled patients with type 2 diabetes mellitus and acute coronary syndrome (ACS) requiring hospitalization. Acute coronary syndrome included myocardial infarction, with or without ST segment elevation on the electrocardiogram, or biomarker negative unstable angina. Exclusion criteria included symptomatic heart failure, hospitalization with heart failure within the previous 12 months, severe peripheral edema, estimated glomerular filtration rate of <45 mE/min/1 .73 m2) or fasting triglyceride level greater than 400 mg/dL. Patients could be randomized at hospital discharge following the qualifying ACS event or after a screening period of no longer than 12 weeks to allow stabilization of their clinical condition, completion of planned revascularization
procedures and achievement of steady-state renal function.
Patients were assigned in a double-blind fashion under a 1 : 1 ratio using a permuted block randomization without stratification through an interactive telephone and web system to receive aleglitazar, 150 ug daily or matching placebo, in addition to
contemporary and guideline-based care for ACS, diabetes, and coronary heart disease risk factors. Concomitant use of systemic corticosteroids for longer than 2 weeks,
thiazolidinediones or fibrates was not permitted. Patients returned for outpatient visits at 1 , 3, 6, 9, and 12 months following randomization, followed by alternating visits and phone contact every third month thereafter. The study drug was not interrupted until the repeated test of serum creatinine value was superior to 50% increase over the baseline visit.
We surprisingly found out in AleCardio that aleglitazar could stabilize the kidney function in diabetic kidney disease (DKD) patients who would have linear decrease of eGFR (estimated glomerular filtration rate). We also surprisingly found that aleglitazar could decrease the cardiovascular (CV) risk in Type 2 Diabetes patients with Chronic Kidney Disease (CKD) and dyslipidemia. This is of particular importance since the majority of DKD/CKD patients pass away due to CV events before they reach end stage renal disease (ESRD). The patients who had a higher CV risks (i.e. CKD patients with dyslipidemia) were selected for the analysis of the MACE outcome. Considering that low HDL-C is one of the unique dyslipidemia characters in CKD patients, this subset of higher risk patients was defined as eGFR<60 mL/min and HDL-C<40mg/dL. Both cutoffs are based on well accepted clinical criteria for CKD (Stage 3) or dyslipidemia (low HDL-C). The baseline charcteristics were balanced in both treatment arms in this subset population, as can be seen in Table 1.
Table 1. Baseline characteristics in the subset of AleCardio patients with CKD and dyslipidemia.
eGFR<60 ml/min and
HDL-C <40 mg/dL
Aleglitazar Placebo
n 317 295
Age (yr) 66 65
Weight (Kg) mean 82.2 85.3
BMI 28.9 29.8
Duration of T2DM (yr) 10.0 10.8
HA1C (%) 7.7 7.7
eGFR (ml/min/1.73m2) 50.3 50.3
UACR>300 mg/g (%) 9.46 13.9
HDL-C (mmol/1) 0.87 0.86
(mg/dL)
(33.59) (33.20)
LDL-C (mmol/1) 1.95 2.01
(mg/dL)
(75.29) (77.61)
TG (mmol/1) 2.0 2.1
NT-proBNP (ng/ml) 1536.6 1587.4
ACS Index Events
STEM (%) 44 44
NSTEM (%) 32 33
Unstable angina (%) 24 23
Diabetes Medications (%)
Metformin / Sulfonylureas / Insulin 60 / 41 / 28 59 / 38 / 37 Cardiac Medications (%)
Aspirin / ADP Inhibitor 92 / 88 94 / 87
Statins 92 93
RAS inhibitor 85 85
Surprisinlgy, the relative risk reduction of the MACE endpoint in aleglitazar treatment was 32% over the placebo group of AleCardio patients having CKD and dyslipidemia (HR 0.68, 95% Cl 0.44, 1.04, p=0.07). This was much higher than that in the overall AleCardio population. Interestingly, a significant MACE risk reduction was observed in Asian patients in general (Relative Risk Reduction 29%); moreover, the relativle risk reduction was much higher (up to 70%) in the subgroup of Asian patients having CKD with dyslipidemia. This is demonstrated by the data presented in Figures 1 and 2.
Figure 1 represents the time to first event of MACE endpoint in AleCardio patients with baseline eGFR<60mL/min and HDL-C<40mg/dL. Figure 2 shows the comparision of MACE endpoint in different subgroups. Major adverse cardiac events (MACE): composite of cardiovascular death, non-fatal MI or non- fatal stroke.
In a further analysis of AleCardio safety data, and in particular the PPAR agonist- related safety data, aleglitazar treatment showed a balanced safety profile in heart failure, serious renal dysfunction, and severe GI bleeding in the subset of patients with CKD and dyslipidemia, as shown in Table 2.
Table 2
Safety Data GFR<60 + HDL-C <40 Overall Population
Aleglitazar Placebo Aleglitazar Placebo
n 317 295 3,587 3,587
Hypoglycemia 20.2% 2 15.6% 16.9% 2 11.0%
Heart Failure 8.8% / 5.0% 1 8.8% / 7.1% 6.9% /4.6% 3 5.0% /3.8%
(any/Serious)
Serious Renal AE 3.2% 2 2.7% 1.4% 2 0.9%
Bone fracture 2.2% 2 1.4% 2.3% 2 1.8%
Severe Gl Bleeding 1.6% 1 1.7% 1.5% 2 0.9% 1 Optimistic; 2 On Target; 3 Minimal or killing for safety
(based on aleglitazar Target Product Profile)
The invention thus relates to aleglitazar for use in treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia. The invention also relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having a GFR inferior to 60 mL/min and a HDL-C level inferior to 40 mg/dL.
The invention further relates to aleglitazar for use as defined above, wherein chronic kidney disease is diabetic kidney disease. The invention further relates to aleglitazar for use as defined above, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non- fatal stroke. The invention also relates to aleglitazar for use as defined above, wherein the patient is of Asian ethnicity.
“Asian ethnicity” refers to a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including, for example,
Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. Reference: FDA 2005 Guidance for Industry - Collection of Race and Ethnicity Data in Clinical Trials.
CKD is generally defined as kidney damage for at least 3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR; or GFR <60 mL/min/1 73m2 for at least 3 months, with or without kidney damage.
DKD is a subset of CKD, wherein the patient has diabetes induced kidney injury and albuminuria.
Type 2 Diabetes, like CKD and DKD, is a well characterized disease and its diagnosis criteria are established by the World Health Organization.
The invention also relates to aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity.
The invention relates in particular to aleglitazar for use as defined above wherein aleglitazar is for oral use at a dose of 150 ug once a day.
The invention further relates to:
The use of aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia;
The use of aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient having a GFR inferior to 60 mF/min and a HDF-C level inferior to 40 mg/dF;
The use as defined above, wherein chronic kidney disease is diabetic kidney disease;
The use as defined above, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non-fatal stroke; and
The use as defined above, wherein the patient is of Asian ethnicity. The invention also relates to the use of aleglitazar in the manufacture of a medicament for treating or preventing major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity.
The invention relates in particular to a use as defined above wherein aleglitazar is for oral use at a dose of 150 ug once a day.
The invention further relates to:
A method for the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia comprising the administration of aleglitazar to a patient in need thereof; A method for the treatment or prevention of major adverse cardiac events in a Type
2 Diabetes patient having a GFR inferior to 60 mL/min and a HDL-C level inferior to 40 mg/dL comprising the administration of aleglitazar to a patient in need thereof;
A method as defined above, wherein chronic kidney disease is diabetic kidney disease; A method as defined above, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non-fatal stroke; and
A method as defined above, wherein the patient is of Asian ethnicity.
The invention aslo relates to a method for the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity comprising the administration of aleglitazar to a patient in need thereof.
The invention relates in particular to method as defined above wherein aleglitazar is orally administered at a dose of 150 ug once a day.
In the present invention, the patient can in particular be a patient suffering from acute coronary syndrome.

Claims

Claims
1. Aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having chronic kidney disease and dyslipidemia.
2. Aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient having a GFR inferior to 60 mL/min and a HDL-C level inferior to 40 mg/dL.
3. Aleglitazar for use according to claim 1, wherein chronic kidney disease is diabetic kidney disease.
4. Aleglitazar for use according to any one of claims 1 to 3 wherein the patient is of Asian ethnicity.
5. Aleglitazar for use in the treatment or prevention of major adverse cardiac events in a Type 2 Diabetes patient of Asian ethnicity.
6. Aleglitazar for use according to any one of claims 1 to 5, wherein major adverse cardiac events are cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
7. Aleglitazar for use according to any one of claims 1 to 6, wherein aleglitazar is for oral use at a dose of 150 ug once a day.
8. The invention as hereinbefore described.
Figure imgf000009_0001
PCT/EP2019/052539 2019-02-01 2019-02-01 Aleglitazar for use in the treatment or prevention of major adverse cardiac events WO2020156683A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/052539 WO2020156683A1 (en) 2019-02-01 2019-02-01 Aleglitazar for use in the treatment or prevention of major adverse cardiac events

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/052539 WO2020156683A1 (en) 2019-02-01 2019-02-01 Aleglitazar for use in the treatment or prevention of major adverse cardiac events

Publications (1)

Publication Number Publication Date
WO2020156683A1 true WO2020156683A1 (en) 2020-08-06

Family

ID=65278369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/052539 WO2020156683A1 (en) 2019-02-01 2019-02-01 Aleglitazar for use in the treatment or prevention of major adverse cardiac events

Country Status (1)

Country Link
WO (1) WO2020156683A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092084A1 (en) 2001-05-15 2002-11-21 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092084A1 (en) 2001-05-15 2002-11-21 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. MICHAEL LINCOFF ET AL: "Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 311, no. 15, 16 April 2014 (2014-04-16), US, pages 1515, XP055330431, ISSN: 0098-7484, DOI: 10.1001/jama.2014.3321 *
LINCOFF ET AL., AM HEART J., vol. 166, no. 3, 2013, pages 429 - 434
LINCOFF ET AL., JAMA, vol. 311, no. 15, 2014, pages 1515 - 1525
LUIS RUILOPE ET AL: "Effects of the dual peroxisome proliferator-activated receptor-?/? agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study", BMC NEPHROLOGY, BIOMED CENTRAL, LONDON, GB, vol. 15, no. 1, 18 November 2014 (2014-11-18), pages 180, XP021206744, ISSN: 1471-2369, DOI: 10.1186/1471-2369-15-180 *

Similar Documents

Publication Publication Date Title
Kaul Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials
Rosenstock et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Boyle et al. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
McGill et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study
Ali et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
Marik et al. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria
Newcomer et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Nitti et al. Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial
Ortiz et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
Goodman et al. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
JP2015164964A5 (en)
Abdul-Ghani et al. Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT
Dillinger et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients
Isaacson et al. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303)
Niessner et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Filozof et al. Effect of vildagliptin as add-on therapy to a low-dose metformin
Rosenstock et al. Long‐term 2‐year safety and efficacy of vildagliptin compared with rosiglitazone in drug‐naïve patients with type 2 diabetes mellitus
Anker et al. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
Heerspink et al. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials
Khangura et al. Diabetes and hypertension: clinical update
Assunção et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine
Rodriguez et al. Cardiovascular disease leads to a new algorithm for diabetes treatment
Dobbins et al. GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial
Banerjee et al. Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
EP3215138A1 (en) Methods of treating ckd using predictors of fluid retention

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19703071

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19703071

Country of ref document: EP

Kind code of ref document: A1